Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines

AM Bergman1, HM Pinedo1, I Talianidis2, G Veerman1, WJP Loves1, CL van der Wilt1 and GJ Peters*,1

1Department Medical Oncology, VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands; 2Institute of Molecular Biology and Biotechnology, FORTH, 1527 Vassilika Vouton, 71110 Herakleion Crete, Greece

Gemcitabine (2',2'-difluorodeoxycytidine) is a deoxycytidine analogue that is activated by deoxycytidine kinase (dCK) to its monophosphate and subsequently to its triphosphate dFdCTP, which is incorporated into both RNA and DNA, leading to DNA damage. Multidrug resistance (MDR) is characterised by an overexpression of the membrane efflux pumps P-glycoprotein (P-gP) or multidrug resistance-associated protein (MRP). Gemcitabine was tested against human melanoma, non-small-cell lung cancer, small-cell lung cancer, epidermoid carcinoma and ovarian cancer cells with an MDR phenotype as a result of selection by drug exposure or by transfection with the mdr1 gene. These cell lines were nine- to 72-fold more sensitive to gemcitabine than their parental cell lines. The doxorubicin-resistant cells 2R120 (MRP1) and 2R160 (P-gP) were nine- and 28-fold more sensitive to gemcitabine than their parental SW1573 cells, respectively (P<0.001), which was completely reverted by 25 μM verapamil. In 2R120 and 2R160 cells, dCK activities were seven- and four-fold higher than in SW1573, respectively, which was associated with an increased dCK mRNA and dCK protein. Inactivation by deoxycytidine deaminase was 2.9- and 2.2-fold decreased in 2R120 and 2R160, respectively. dFdCTP accumulation was similar in SW1573 and its MDR variants after 24 h exposure to 0.1 μM gemcitabine, but dFdCTP was retained longer in 2R120 (P<0.001) and 2R160 (P<0.003) cells. 2R120 and 2R160 cells also incorporated four- and six-fold more [3H]gemcitabine into DNA (P<0.05), respectively. P-glycoprotein and MRP1 overexpression possibly caused a cellular stress resulting in increased gemcitabine metabolism and sensitivity, while reversal of collateral gemcitabine sensitivity by verapamil also suggests a direct relation between the presence of membrane efflux pumps and gemcitabine sensitivity.

Keywords: gemcitabine; multidrug resistance; collateral sensitivity; deoxycytidine kinase; thymidine kinase

Gemcitabine (2',2'-difluorodeoxycytidine) is a deoxycytidine analogue with proven activity in ovarian, pancreatic and non-small cell lung cancer (NSCLC) in vivo, in vitro and in the clinic (Abratt et al, 1994; Lund et al, 1994; Braakhuis et al, 1995; Heinemann, 2001). Deoxycytidine kinase (dCK) phosphorylates both deoxycytidine (dCyd) and gemcitabine to their monophosphates, which are subsequently phosphorylated to deoxycytidine triphosphate (dCTP) and gemcitabine triphosphate (dFdCTP), respectively. Gemcitabine can be inactivated by deamination catalysed by deoxycytidine deaminase (dCDA) (Heinemann et al, 1988). dFdCTP can be incorporated into both DNA and RNA (Huang et al, 1991; Ruíz van Haperen et al, 1993b). The mitochondrial enzyme thymidine kinase 2 (TK2) phosphorylates the natural nucleosides thymidine and deoxycytidine, but also gemcitabine, although, to a lesser extent than dCK (Eriksson et al, 1991; Bergman et al, 1999). This is in contrast to the cytosolic enzyme thymidine kinase 1, which does not phosphorylate deoxycytidine (Eriksson et al, 1991). Since dCTP is the major natural feedback inhibitor of dCK and competes with dFdCTP for DNA polymerase, an increase in dCTP pools will decrease gemcitabine sensitivity (Heinemann et al, 1990; Ruíz van Haperen and Peters, 1994).

Crossresistance to some structurally and functionally unrelated natural-derived drugs (e.g. daunomycin, etoposide, vincristine) is called multidrug resistance (MDR). Multidrug resistance is caused by overexpression of the plasma membrane drug efflux pumps P-glycoprotein (P-gP), the product of the mdr1 gene, and multidrug resistance-associated protein (MRP) (Endicott and Ling, 1989; Grant et al, 1994). These pumps can be blocked by verapamil (Cornwell et al, 1987). The MRP family currently has seven members, all with different drug specificities (Borst et al, 2000). Although gemcitabine is a substrate for MRPs efflux pump (Davidson et al, 2002), it is predominantly transported into the cell across cell membranes via facilitated diffusion (equilibrative nucleoside transporter, ENT) and sodium-dependent concentrative mechanisms (concentrative nucleoside transporter, CNT) (Mackey et al, 1998, 1999; Ritzel et al, 2001). Jensen et al (1997) observed that some small-cell lung cancer (SCLC) cells with P-gP overexpression were more sensitive to gemcitabine and the structurally related deoxycytidine analogue 1-β-D-arabinofuranosylcytidine (cytarabine, ara-C), although Grant et al (1995) observed crossresistance to ara-C in a P-gP-overexpressing leukaemia cell line.

*Correspondence: Dr GJ Peters; E-mail: gj.peters@vumc.nl
Received 17 October 2002; revised 4 April 2003; accepted 13 April 2003

British Journal of Cancer (2003) 88, 1963 – 1970
© 2003 Cancer Research UK All rights reserved 0007 – 0920/03 $25.00
www.bjcancer.com
We tested the sensitivities to gemcitabine of various pairs of cell lines and their MDR variants derived from different human tumours. The human NSCLC cell line SW1573 and its P-gP- and MRP1-overexpressing variants were used for mechanistic studies on gemcitabine sensitivity of MDR cells. Moreover, a possible role of the membrane efflux pumps in gemcitabine sensitivity was investigated.

MATERIALS AND METHODS

Chemicals and reagents

Dulbecco’s modified eagle’s medium (DMEM) and Roswell Park Memorial Institute (RPMI) medium were purchased from Flow Laboratories (Irvine, UK); foetal calf serum from Life Technologies (New York, NY, USA); trichloroacetic acid (TCA), glutamine and gentamicin from Merck (Darmstadt, Germany); trypsin and sulphorhodamine B (SRB) from Sigma Chemical Co. (St Louis, USA); and VP-16 (etoposide) from Bristol-Myers Squibb (Weesp, the Netherlands). Eli Lilly (Indianapolis, IN, USA) kindly supplied gemcitabine and [5-3H]gemcitabine (16.7 Ci mmol⁻¹). [5-3H]Deoxycytidine was purchased from Moravek (Brea, CA, USA) and was found to be negative. [3H]Uridine (58.8 Ci mmol⁻¹) was from Dupont de Nemours NEND (Dreiech, Germany) and [5-3H]uridine (27.8 Ci mmol⁻¹) from Amersham International (Buckinghamshire, England). All other chemicals were of analytical grade and commercially available.

Cell culture

The in vitro experiments were performed with five parental cell lines and eight MDR variants (Table 1). All cell lines were grown in monolayers in DMEM, except for GLC4S and GLC4/ADR, which grow in several layers, but are only loosely attached to the flask. Both media were supplemented with 7.5% heat-inactivated foetal calf serum, and 250 ng ml⁻¹ gentamicin. Cells were regularly contaminated by using a rapid detection system with a 3H-labelled DNA probe (Gen-Probe, San Diego, CA, USA) and were found to be negative.

Table 1  MDR phenotype, sensitivity to gemcitabine and sensitivity factors of human cancer cell lines

| Cell line  | Origin        | MDR phenotype | Doubling time (h) | IC₅₀ (nm) gemcitabine | Sensitivity factor |
|------------|---------------|---------------|-------------------|-----------------------|-------------------|
| SW1573     | NSCLC         | Parental      | 35 ± 5            | 170 ± 2               | 1                 |
| 2R120⁰     |               | DOX resistant, MRP1 | 50 ± 6         | 1.9 ± 1.2             | 89**              |
| 2R160⁰     |               | DOX resistant, P-gP | 50 ± 6         | 0.6 ± 0.4             | 27.9***            |
| SW1573S1(1.1)⁰ |           | P-gP transfected | 30 ± 2           | 5.7 ± 2.4             | 3.0**              |
| SW1573S1(MRP)⁰ |            | MRP1 transfected | 35 ± 8           | 0.05 ± 0.02           | 340***             |
| GLC4       | SCLC          | Parental      | 22 ± 5            | 4.1 ± 0.6             | 1                 |
| GLC4/ADR⁰  |               | DOX resistant, MRP1 | 31 ± 9         | 0.4 ± 0.2             | 11*               |
| A2780       | Ovarian       | Parental      | 22 ± 9            | 1.6 ± 0.3             | 1                 |
| 2780AD⁴     |               | DOX resistant, P-gP | 26 ± 8         | 0.03 ± 0.03           | 55**              |
| KB3-1       | Epidermoid    | Parental      | 16 ± 3            | 59 ± 24               | 1                 |
| KB3-5⁰      |               | Colchicine resistant, P-gP | 19 ± 5    | 330 ± 20              | 1.8 NS             |
| BRO         | Melanoma      | Parental      | 21 ± 3            | 300 ± 87              | 1                 |
| BROndr⁰     |               | P-gP transfected | 29 ± 4          | 33 ± 12               | 9.0**              |

MDR = multidrug resistance; NSCLC = non-small-cell lung cancer; SCLC = small-cell lung cancer; DOX = doxorubicin; P-gP = P-glycoprotein; MRP = multidrug resistance-associated protein. Cells were exposed to gemcitabine for 72 h. Values represent the mean IC₅₀ ± s.d. of at least three experiments. IC₅₀ = 50% growth-inhibitory concentration, sensitivity factor = IC₅₀ parental/IC₅₀ MDR variant. Statistical analysis by t-test (independent samples); NS = not significant, *P<0.05, **P<0.01, ***P<0.001. References: ¹Kuiper et al (1990). ²Zaman et al (1993). ³Zaman et al (1994). ⁴Louie et al (1986).

Chemosensitivity testing

The determination of the IC₅₀ (the drug concentration causing 50% growth inhibition) in monolayer cell lines was performed using the SRB assay. The assay was performed using the NCI protocol with some small modifications (Skehan et al, 1990; Keepers et al, 1991). For GLC4S and GLC4/ADR, both growing as semimultilayers, the tetrabrazilum (MTT) assay was performed as previously described (Keepers et al, 1991). Culture conditions were optimised for all cell lines. For both assays, the cells were plated in 96-well plates at day 1, in different densities, depending on their doubling times (4000–15 000 cells per well). The optimal plating number was the highest number of cells, which enabled log-linear growth for 4 days. Log-linear growth or exponential growth is the phase of growth in which each descendant of the parental cell will divide as well.

On day 2, cells were exposed to gemcitabine (final concentrations ranged from 5 × 10⁻⁶ to 5 × 10⁻⁵ M), with or without 25 µM verapamil for 72 h and optical density (OD) was estimated either by the SRB or MTT assay and set at 100%; the OD of the cells at the day of drug administration was set at 0%. The IC₅₀ was the drug concentration resulting in a relative OD of 50%, total growth inhibition when OD was similar to the initial value, 0%, and an OD lower than the initial value 0% represents cell kill (Peters et al, 1993).

dCK enzyme activity

For determination of dCK activities, 10 000 g supernatants were prepared with cold dCK buffer, containing 0.3 M Tris-HCl (pH 8.0), essentially as described (Ruiz van Haperen et al, 1993a). Protein content was estimated with the Biorad protein assay. To 25 µl of supernatant containing 0.2–4.0 × 10⁷ cells, 25 µl of a substrate mixture was added (final concentrations: 10 mM ATP, 5 mM MgCl₂, 30 mM Tris-HCl and 230 µM [14C]thymidine (final specific activity 0.04 Ci mmol⁻¹)), with or without 1 mM thymidine to inhibit TK2-mediated phosphorylation of dCyd (Eriksson et al, 1991), and incubated at 37°C for 15 min. The radio-labelled product dCMP was quantitated in a liquid scintillation counter, after thin layer chromatography on polyethylenimine cellulose layers.
Increased sensitivity to gemcitabine of P-gP
AM Bergman et al

dCDA enzyme activity
Activity of dCDA was determined as described earlier (Ruiz van Haperen et al, 1993a). Briefly, 10 000 g supernatants were prepared and enzyme assays were performed at 37°C in 1–5 × 10^6 cells with 500 μM dCyd as a substrate for 15 or 25 min. The deaminated product deoxyuridine was analysed using reversed phase high-performance liquid chromatography (HPLC) (Ruiz van Haperen et al, 1993a).

Quantitative reverse transcriptase–polymerase chain reaction assay for dCK-mRNA with competitive templates
RNA was extracted from confluent growing cells using the RNAzole method and cDNA samples were prepared as previously described (Rots et al, 2000). Competitive template reverse transcriptase–polymerase chain reaction (RT-PCR) assays for dCK mRNA and the housekeeping gene β-actin were performed as described previously (Kroep et al, 2002). Levels of expression were reported as units of dCK-mRNA/10^6 β-actin mRNA molecules.

Western blot for dCK
Western blotting by affinity-purified rabbit antibody against human dCK was performed as previously described (Hatzis et al, 1998).

dFdCTP accumulation and retention
For dFdCTP accumulation and retention, cells were plated in six-well plates at 0.5–1.0 × 10^6 cells per well in 2 ml medium, and exposed to 0.1 or 1.0 μM gemcitabine for 24 h. For the retention, cells were cultured in drug-free medium for 4 or 24 h after incubation. After harvesting, nucleotides were extracted and quantitated with HPLC as previously described (Van Moorsel et al, 1994).

[^3H]Gemcitabine incorporation into DNA and RNA
Incorporation studies were performed using 96-well filter plates essentially as described previously (Van der Wilt et al, 1993; Van Moorsel et al, 1999a). A total of 1.0 × 10^6 cells per well were plated in a volume of 100 μl, whereafter 100 μl of [^3H]gemcitabine containing medium (4 Ci mmol^-1) was added resulting in final concentrations of 0.1 or 1.0 μM. After 24 h incubation, the medium was removed by suction through the filters. Filters were washed with TCA and phosphate-buffered saline (PBS), followed by incubation with RNase A or without RNase A at 37°C. After termination of the reaction, the filters were washed again with TCA, H2O and 70% ethanol, removed and radioactivity was counted as described previously (Van Moorsel et al, 1999a). Counts in wells incubated with RNase A were considered to represent [^3H]gemcitabine incorporated into DNA, the difference in counts between incubation with or without RNase A was considered to represent [^3H]gemcitabine incorporation into RNA. To correct for DNA and RNA synthesis, experiments were performed simultaneously with cells exposed to 0.1 or 1.0 μM cold gemcitabine and 5.6 μM [^3H]thymidine (62.8 mCi mmol^-1) or 0.165 μM [^3H]uridine (25 Ci mmol^-1). Cell numbers were estimated by performing this experiment with cells exposed to unlabelled gemcitabine in a concentration of 0.1 or 1.0 μM (Van Moorsel et al, 1999a).

Fluorometric analysis of DNA unwinding assay
To measure the gemcitabine-induced DNA damage, the fluorometric analysis of DNA unwinding (FADU) assay was used (Birnboim and Jevcak, 1981; Bergman et al, 1996). Essentially, 3 × 10^6 cells were incubated for 24 h at 37°C with gemcitabine in a concentration of 0.1 or 1.0 μM. Cells exposed to 50 μM VP-16 for 24 h were used as a positive control, since this drug is known to introduce double-strand (ds) DNA breaks very effectively, and cells not exposed to drugs were used as a negative control. Cells were lysed and exposed to an alkaline environment, allowing the DNA to unwind. The extent of strand breaks in the DNA determines the extent of DNA unwinding at the end of incubation. The dsDNA was stained by ethidium bromide and the ratio of fluorescence between treated and control samples was used to determine the percentage dsDNA (Bergman et al, 1996).

Statistical analysis
In case of significant differences between parental and MDR cells, a t-test was used to compare unpaired data of the two cell lines. The computer program SPSS (version 7.5, SPSS, Inc., Chicago, IL, USA) was used for statistical analysis.

RESULTS

Growth inhibition tests
The parental cell lines showed large differences in sensitivity to gemcitabine, which was not related to their doubling time, this indicates that differences in metabolic activation and mechanisms of action are predominantly responsible for sensitivity to gemcitabine. As a control, clonogenic assays were performed for some cell lines as described previously (Bergman et al, 2000), which also showed a similar difference in sensitivity (data not shown). SW1573 cells were intermediately sensitive to gemcitabine compared to the other parental cells; BRO, GLC4, KB3-1 and A2780 cells. All SW1573 variants were significantly (P<0.01) more sensitive to gemcitabine than the parent (Figure 1, Table 1). 2R120 and 2R160 cells, the MRP1- and P-gP-overexpressing variants of SW1573, respectively, were nine- and 28-fold more sensitive to gemcitabine, respectively. The P-gp-transfected variant S1(1.1) was three-fold more sensitive, but the largest difference was found for the MRP1-transfected S1(MRP) cells, which were 340-fold more sensitive to gemcitabine than SW1573 cells (P<0.001). The doxorubicin-selected, MRP1-overexpressing variant of GLC4, GLC4/ADR, was 11.1-fold more sensitive to gemcitabine than its parental cells (P<0.05). The human ovarian cancer A2780 cells were the most sensitive parental cells, but the doxorubicin-
resistant P-gP-overexpressing variant 2780AD was even more sensitive to gemcitabine (P < 0.01). KB8-5 cells were included since P-gP was induced by exposure to colchicine; also this phenotype was associated with increased sensitivity to gemcitabine. BRO cells were the least sensitive of the parental cells tested, but its mdr1-transfected variant was significantly more sensitive (P < 0.01).

The MDR phenotype of doxorubicin resistance can be reversed by the calcium-channel blocker verapamil. This phenomenon has been used as a characteristic of the efflux pump. In order to determine whether the activity of the pump was associated with the collateral sensitivity to gemcitabine, we exposed SW1573 and its variants to gemcitabine and verapamil. Verapamil almost completely reversed the gemcitabine sensitivity to the level of the parental SW1573 cells (Figure 2). This reversal was significant in 2R160 and S1(MRP) cells (P < 0.05).

### Deoxycytidine kinase, thymidine kinase 2 and deoxycytidine deaminase assays

Since gemcitabine cytotoxicity is dependent on its phosphorylation, we determined the activities of the enzymes involved in this process. SW1573 cells had the lowest dCK activity, this activity was 6.6- and 4.0-fold higher in 2R120 (P < 0.001) and 2R160 cells (not significant), respectively (Table 2). In 2R120 cells, TK2 activity was unchanged compared to its parental SW1573 cells. However, TK2 activity was two-fold lower in 2R160 than in SW1573 cells (not significant).

The amount of dCK protein present in the cell as determined with Western blots, revealed a 7.2- and 2.2-fold higher expression in 2R120 and 2R160 cells, respectively, than in the parental SW1573 cells (Table 2). In order to determine whether the increase in dCK protein was the result of increased expression, we determined the expression of dCK-mRNA (Table 2). The dCK/β-actin ratio was 6.1- and 5.5-fold higher in 2R120 and 2R160 cells than in the parental SW1573 cells, respectively (P < 0.001).

dCDA activity was decreased 2.9- and 2.2-fold in 2R120 and 2R160 cells, respectively (Table 2).

### dFdC accumulation and retention

The active metabolite of gemcitabine is dFdC. Besides its accumulation, retention is also important for the cytotoxicity of gemcitabine. No significant difference in dFdC accumulation was found between the cell lines, both at 0.1 and 1.0 μM gemcitabine (Figure 3).

| Enzyme | SW1573 | 2R120 | 2R160 |
|--------|--------|-------|-------|
| dCK    | 0.3±0.08| 2.1±0.2***| 1.3±0.7 NS |
| Protein| 0.3     | 2.0   | 0.6   |
| mRNA   | 0.5     | 3.1   | 2.8   |
| TK2    | 0.2±0.2 | 0.2±0.3| 0.1±0.2 NS |
| dCDA   | 37±30  | 13±3***| 17±3*** |

Enzyme activities are means±s.d. of at least three experiments in nmol h⁻¹ per 10⁶ cells. For dCK and TK2 activity, dCyd was used as a substrate with or without thymidine to block TK2 activity. The difference in dCIMP formation between dCyd as a substrate and dCyd and thymidine as a substrate was considered as TK2 activity. The protein content of SW1573, 2R120 and 2R160 cells was about 273±77, 442±152 and 210±8 μg per 10⁶ cells, respectively (means±s.d.). Protein and mRNA expression are means of two and three separate experiments in (OD mm⁻¹) and (dCK/β-actin × 10⁻²), respectively. Statistically different from SW1573 by t-test (independent samples); NS = not significant, ***P<0.001.

In all cells, accumulation was concentration dependent, six- to eight-fold more dFdC accumulated at 1.0 μM than at 0.1 μM gemcitabine. At 0.1 μM gemcitabine, dFdC accumulation was retained longer in 2R120 (P = 0.0001) and 2R160 (P = 0.0003) cells than in the parental cell line SW1573. At 1.0 μM gemcitabine, no difference in retention of dFdC was found between the cell lines. Another active metabolite of gemcitabine, gemcitabine-diphosphate was not detectable.

### Gemcitabine incorporation into DNA and RNA, and DNA damage

Following its accumulation, dFdC may be incorporated into DNA and RNA. The extent and retention are dependent on DNA and RNA polymerases, but also on subsequent excision. We not only determined the total extent of incorporation but also its relation to synthesis of DNA and RNA, which are inhibited by gemcitabine. SW1573, 2R120 and 2R160 cells not exposed to gemcitabine incorporated 53±29, 8.7±5.0 and 41±9 pmol...
In this paper, we describe an increased collateral sensitivity to gemcitabine in five pairs of cell lines with an MDR phenotype. Collateral sensitivity is defined as an increased sensitivity to one class of drugs, while made resistant to another class of drugs. This increased sensitivity was associated with an increase in the activity of dCK in the variant cell lines. Apparently, the increased dCK activity was related to an upregulation of the gene, reflected by an increased mRNA and protein content of the cells. Moreover, the increased dCK activity was stable for many passages, indicating the structural nature of the upregulation of the gene. Deoxycytidine kinase plays a pivotal role in gemcitabine activation since it catalyzes the first step in phosphorylation, which is rate limiting for further phosphorylation to active metabolites. This is based on the observation that dCK deficiency is associated with gemcitabine resistance (Bergman et al, 1999, 2000) which can be reverted by transfection with human dCK (Van der Wilt et al, 2000). The increased dCK activity is the most logical explanation for the collateral sensitivity in MDR cells, while the decreased dCD A activity may add to enhanced intracellular gemcitabine levels available for phosphorylation. However, the role of dCD A activity in gemcitabine sensitivity is still not clear (Bergman et al, 2002). The levels of both dCK mRNA and protein were also higher in 2R120 and 2R160 cells. Comparable differences in dCK levels have been associated previously with differences in gemcitabine sensitivity (Kroep et al, 2002). The increase in the activating enzyme was not only associated with increased retention of dFdCTP pools, but also with more gemcitabine incorporation into DNA.

Jensen et al (1997) previously described that daunorubicin- and VM-26-resistant MDR variants of human SCLC cell lines were also more sensitive to gemcitabine and to the structurally and functionally related deoxycytidine analogue ara-C. However, the extent of collateral sensitivity to gemcitabine and ara-C in the SCLC cell lines was less than that for the present cell lines, although in the SCLC line also an increased dCK activity was present (Bergman et al, 2001a). In addition to these cell lines, an increase in ara-C sensitivity was found in refractory AML cells displaying a P-gp or MRP overexpression after treatment with MDR drugs (Schuurhuis et al, 1995). It was suggested that exposure of cells to an MDR drug might select for a subpopulation of P-gp- or MRP-overexpressing cells with the most favourable enzymatic profile for cell survival. Our in vitro data suggest that the selection process may involve an increase in dCK.

In the discussion of the structural increase in dCK, Sasvari-Szekely et al (1998) reported that in human lymphocytes, inhibition of DNA synthesis by 2-chloro-2’ deoxyadenosine (Cl-Ado) resulted in a rapid, transient rise of dCK activity, which was however, not associated with an increase in the amount of dCK, while dCK mRNA levels even decreased. Apparently, dCK itself was activated, probably through a post-translation modification. Moreover, since dCK is a major enzyme in the supply of essential deoxynucleotides via the salvage pathway for DNA repair, its activation might be part of the cellular restoration process occurring after drug treatment. Unlike the transient increase in dCK activity in human lymphocytes during Cl-Ado exposure, the increase in dCK activity found in our NSCLC cell lines seemed to be stable. In 2R120 and SW1573 cells, 40% of the dCyd phosphorylation was the result of TK activity, while in 2R160 the TK activity was two-fold lower.

Increased sensitivity to gemcitabine is the result of the extent of its incorporation and efficacy of the DNA repair mechanisms. In SW1573 and 2R120 cells, the amount of dSNA breaks was concentration dependent (7 and 9% dSNA breaks at 0.1 μM, 16 and 39% dSNA breaks at 1 μM gemcitabine, respectively). However, in 2R160 comparable DNA damage was found at 0.1 and 1.0 μM gemcitabine (19 and 25% dSNA breaks, respectively).
Increased sensitivity to gemcitabine of P-gp

AM Bergman et al

British Journal of Cancer (2003) 88 (12), 1963 – 1970

Bergman AM, Munch-Petersen B, Jensen PB, Sehested M, Veerman G, Voorn DA, Smid K, Pinedo HM, Peters GJ (2001a) Collateral sensitivity to gemcitabine (2',2'-difluorodeoxycytidine) and cytotoxic arabinoside of doxorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines. Biochem Pharmacol 61: 1401 – 1408

Bergman AM, Pinedo HM, Peters GJ (2001b) Steroids affect collateral sensitivity to gemcitabine of multidrug-resistant human lung cancer cells. Eur J Pharmacol 416: 19 – 24

Bergman AM, Pinedo HM, Peters GJ (2002) Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine). Drug Resist Update 5: 19 – 33

Bergman AM, Pinedo HM, Jongma APM, Brouwer M, Ruiz van Haperen VWT, Veerman G, Leyva A, Eriksson S, Peters GJ (1999) Decreased resistance to gemcitabine of cytotoxic arabinoside resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinase. Biochem Pharmacol 57: 397 – 406

Bergman AM, Ruiz van Haperen VWT, Veerman G, Kuiper CM, Peters GJ (1996) Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res 2: 521 – 530

Birnboim HC, Jevcak JJ (1981) Fluorometric method for rapid detection of DNA strand breaks in human white blood cells produced by low doses of radiation. Cancer Res 41: 1889 – 1892

REFERENCES

Abratt RP, Rezwoda W, Falkson G, Goedhals L, Hacking D (1994) Efficacy and safety profile of gemcitabine in non-small cell lung cancer. Phase II study. J Clin Oncol 12: 1335 – 1340

Aszalos A, Thompson K, Yin JJ, Ross DD (1999) Combinations of P-glycoprotein blockers, verapamil, PSC833, and cremophor act differently in gemcitabine sensitivity, in contrast to the resistance to, for example, doxorubicin. The observation that verapamil reverted the collateral sensitivity of the MDR cells to gemcitabine suggests a possible relation between the presence of a certain membrane efflux pump activity, gemcitabine sensitivity and a transient regulation of dCK activity. One of these mechanisms may include regulation by protein kinase C (PKC) activity. Several studies report an increase in PKC activity in cells with an overexpression of P-gp or MRP (Beck et al, 1998; Ratnasinghe et al, 1998). P-glycoprotein and MRP are phosphorylated (Ma et al, 1995; Clavy et al, 1997); however, it is a matter of debate whether phosphorylation modulates the pump function (Ma et al, 1995; Smith and Zilfou, 1995; Clavy et al, 1997; Ratnasinghe et al, 1998). Since dCK may be phosphorylated by PKC, and exhibits a higher activity in the phosphorylated state (Wang and Kucera, 1994), PKC might play a role in the collateral sensitivity to gemcitabine of MDR cells.

Since P-gp and MRP act as an efflux pump for steroid hormones, such as cortisol, progesterone and aldosterone (Van Kalen et al, 1993; Mulder et al, 1996) and several studies reported a decrease in TK activity as a result of steroid hormone exposure in chicken embryo retina (Naray et al, 1977; Herzfeld and Raper, 1980; Tesoriere et al, 1989), verapamil might inhibit the efflux of these compounds, leading to a transient downregulation of dCK. Clinically relevant concentrations of the steroid drug dexamethasone inhibited the effect of gemcitabine in cultured human glioma cells (Rieger et al, 1999). Moreover, dexamethasone decreased gemcitabine sensitivity of 2R120 and 2R160 cells, and decreased dCK activity in 2R160 cells, but only in the presence of verapamil (Bergman et al, 2001b).

In conclusion, MRPI- and P-gp-overexpressing cells were more sensitive to gemcitabine than their parental cells. This increased sensitivity was related to dCK and gemcitabine effects on DNA. Since relapsed tumours of patients after treatment with MDR drugs frequently display an MDR phenotype, screening for a P-gp or MRPI overexpression, as a predictor of gemcitabine responsiveness, might be of clinical interest.

ACKNOWLEDGEMENTS

We thank Karin Kuiper and Daphne Voon for technical assistance. This work was supported by grants from the Dutch Cancer Society and by the European Union (Biomed Grant BMH4-CT96-0479).

to dCDP and eventually to a depletion of dCTP pools, which can favour dFdCTP incorporation into DNA (Baker et al, 1991; Plunkett et al, 1995). The dFdCTP accumulation and retention in several human tumour cell lines showed a relation with gemcitabine sensitivity in vitro (Ruiz van Haperen et al, 1994; Van Moorsel et al, 2000). dFdCTP is not only important as a DNA precursor, but also interferes with normal ribonucleotide metabolism, such as inhibition of CTP-synthetase and dCMP-deaminase leading to a depletion of CTP pools and indirectly a decrease of dCTP pools (Heinemann et al, 1990, 1995; Van Moorsel et al, 1999b, 2000). No difference was found in the retention of dFdCTP pools of SW1573 cells and its MDR variants after exposure to 1.0 μM gemcitabine, which might be related to differences in nucleotide transport or 5'-nucleotidase (SNT) activity, known to oppose the action of deoxynucleoside kinases (Bergman et al, 2002). However, MDR variants retained dFdCTP pools longer than SW1573 cells after exposure to 0.1 μM gemcitabine. After 24 h, no detectable dFdCTP pools were found in SW1573 cells, which might be related to the lower dCK activity or altered SNT activity. The concentration-dependent [3H]gemcitabine incorporation into DNA and correlation of DNA damage with sensitivity is in agreement with previous studies in ovarian, colon and leukaemia cell lines (Huang et al, 1991; Ruiz van Haperen et al, 1999b). However, no relation was found between [3H]gemcitabine incorporation into RNA and sensitivity to gemcitabine, leaving a dubious role for RNA incorporation in gemcitabine toxicity (Bergman et al, 2002). Most likely, the increased dFdCTP retention, gemcitabine incorporation and increased sensitivity to gemcitabine are all downstream events of an increased dCK activity, underlining the pivotal role of dCK in gemcitabine sensitivity.

Verapamil is a strong inhibitor of P-gp, but only a partial inhibitor of MRP activity (Aszalos et al, 1999). A concentration of 10 μM verapamil increased sensitivity to doxorubicin of MRPI-transfected NIH/3T3 mouse fibroblasts, but reversal was incomplete (Breuning et al, 1995). Since we used a 2.5-fold higher verapamil concentration, MRPI inhibition might be more effective. Reversal of collateral sensitivity to gemcitabine was found both in P-gp- and MRPI-overexpressing cells. We did not find a direct correlation between the extent of P-gp and MRPI activity and sensitivity to gemcitabine or dCK activity. Apparently, a certain threshold level of P-gp or MRPI activity is required for an increase in gemcitabine sensitivity, in contrast to the resistance to, for example, doxorubicin. The observation that verapamil reverted the
Incremental sensitivity to gemcitabine of P-gP

AM Bergman et al

Adriamycin accumulation and metabolism in adriamycin-sensitive and -resistant human ovarian cancer cell lines. Biochem Pharmacol 35: 467–472

Lund B, Hansen OP, Theilade K, Hansen M, Neij JP (1994) Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 86: 1530–1533

Ma L, Krishnamachary N, Center MS (1995) Phosphorylation of the multidrug resistance associated protein gene encoded protein P190. Biochemistry 34: 3338–3343

Mackey JR, Mani RS, Selner M, Mowles D, Young JD, Belt JA, Crawford CR, Cass CE (1998) Functional nucleoside transporters are required for gemcitabine influx and manifestations of toxicity in cancer cell lines. Cancer Res 58: 4349–4357

Mackey JR, Yao SY, Smith KM, Karpinski E, Baldwin SA, Cass CE, Young JD (1999) Gemcitabine transport in Xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters. J Natl Cancer Inst 91: 1876–1881

Mulder HS, Pinedo HM, Timmer AT, Rao BR, Lankelma J (1996) Multidrug resistance-modifying components in human plasma with potential clinical significance. J Exp Therap Oncol 13: 1–22

Naray A, Aranyi P, Foldes I, Horvath I (1977) Analysis of thymidine kinase activity and glucocorticoid binding capacity in the thymuses of healthy and tumor bearing chickens. J Natl Cancer Inst 59: 1237–1241

Peters GJ, Wets M, Keepers YPM, Oskam R, Van Ark-otje J, Noordhuis P, Smid K, Pinedo HM (1994) Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res 54: 357–361

Grant S, Turner A, Nelms P, Yanovich S (1995) Characterization of a multidrug resistant human erythroleukemia cell line (K562) exhibiting spontaneous resistance to 1β-D-arabinofuranosylcytosine. Leukemia 9: 808–814

Hatzis P, Al-Madhoon AS, Jullig M, Petramis TG, Eriksson S, Talianidis I 273: 2995–3024

Heinemann V (2001) Gemcitabine: progress in the treatment of pancreatic cancer. Oncology 60: 8–18

Heinemann V, Hertel LW, Grindey GB, Plunkett W (1995) Gemcitabine: a mechanism-based inhibitor of the transferase activity of deoxycytidine kinase. Biochem Pharmacol 48: 4024–4031

Heinemann V, Schulz L, Issels RD, Plunkett W (1995) Gemcitabine: a modulator of intracellular nucleotide and deoxynucleoside metabolism. Semin Oncol 22(4 Suppl 11): 11–18

Heinemann V, Xu Y-Z, Chubb S, Sen A, Hertel LW, Grindey GB, Plunkett W (1990) Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine. Mol Pharmacol 38: 567–572

Herzfeld A, Raper SM (1988) Comparison of the sulforhodamine B protein and tetrazolium model systems. Cancer Res 48: 6110–6117

Jensen PB, Holm B, Sorensen M, Christiansen HJ, Sehested M (1997) In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabine. Br J Cancer 38: 869–877

Keopers YP, Pizza PE, Peters GJ, Van Arjk-otje J, Winograd B, Pinedo HM (1991) Comparison of the sulforhabodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing. Eur J Cancer 27: 897–900

Kooper CM, Broxterman HJ, Baas F, Schuurhuis GJ, Haisma HJ, Scheffer GL, Lankelma J, Pinedo HM (1990) Drug transport variants without P-glycoprotein overexpression from a human squamous lung cancer cell line after selection with doxorubicin. J Cell Pharmacol 1: 35–41

Kroep JR, Loves WP, Van der Vliet CL, Alvarez E, Talianidis I, Boven E, Braakhuis BJM, Van Groeningen CJ, Pinedo HM, Peters GJ (2002) Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. J Natl Cancer Inst 94: 371–376

Lincke CR, Van der Bliak AM, Schuurhuis GJ, Van der Velde-Koerts T, Smit JMJ, Borst P (1990) Multidrug-resistance phenotype of human BRO melanoma cells transfected with a wild-type human mdr1 complementary DNA. Cancer Res 50: 1779–1785

Louie KG, Hamilton TC, Wincer MA, Behrens BC, Tsuruo T, Klecker RW, Mckoy WM, Grotzing K, Myers CE, Young RC, Ootol BF (1986)
Shen DW, Fojo A, Chin JE, Roninson IB, Richert N, Pastan I, Gottesman MM (1986) Human multidrug resistant cell lines: increased mdr1 expression can precede gene amplification. Science 232: 643 – 645
Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR (1990) New calorimetric cytotoxicity assay for anticancer drug screening. J Natl Cancer Inst 82: 1107 – 1112
Smith CD, Zilfou JT (1995) Circumvention of P-glycoprotein mediated multiple drug resistance by phosphorylation modulators is independent of protein kinases. J Biol Chem 270: 28145 – 28152
Tesoriere G, Vento R, Taibi G, Calvaruso G, Schiavo MR (1989) Biochemical aspects of chick embryo retina development: the effects of glucocorticosteroids. J Neurochem 52: 1487 – 1494
Van der Wilt CL, Kroep JR, Bergman AM, Loves WJP, Alvarez E, Talianidis I, Van Groeningen CJ, Pinedo HM, Peters GJ (2000) The role of deoxycytidine kinase in gemcitabine cytotoxicity. Adv Exp Med Biol 486: 287 – 290
Van der Wilt CL, Visser GW, Braakhuis BJ, Wedzinga R, Noordhuis P, Smid K, Peters GJ (1993) In vitro antitumour activity of cis- and trans-5-fluoro-5,6-dihydro-6-alkoxy-uracils; effects on thymidylate synthesis. Br J Cancer 67: 702 – 707
Van Kalken CK, Broxterman HJ, Pinedo HM, Feller N, Dekker H, Lankelma J, Giaccone G (1993) Cortisol is transported by the multidrug resistance gene product P-glycoprotein. Br J Cancer 67: 284 – 289
Van Moorsel CJA, Pinedo HM, Veerman G, Bergman AM, Kuiper CM, Vermorken JB, Van der Vijgh WJ, Peters GJ (1999a) Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines. Br J Cancer 80: 981 – 990
Van Moorsel CJA, Pinedo HM, Veerman G, Guechev A, Smid K, Loves WJP, Veerman JB, Postmus PE, Peters GJ (1999b) Combination chemotherapy studies with gemcitabine and etoposide in non-small cell lung and ovarian cancer cell lines. Biochem Pharmacol 57: 407 – 415
Van Moorsel CJA, Bergman AM, Veerman G, Voorn DA, Ruiz van Haperen VWT, Kroep JR, Pinedo HM, Peters GJ (2000) Differential effects of gemcitabine on ribonucleotide pools of twenty-one solid tumour and leukaemia cell lines. Biochim Biophys Acta 1474: 5 – 12
Wang LM, Kucera GL (1994) Deoxycytidine kinase is phosphorylated in vitro by protein kinase C alpha. Biochem Biophys Acta 1224: 161 – 167
Wang L, Munch-Petersen B, Herrstrom Sjoberg A, Hellman U, Bergman T, Jornvall H, Eriksson S (1999) Human thymidine kinase 2: molecular cloning and characterisation of the enzyme activity with antiviral and cytostatic nucleoside substrates. FEMS Lett 443: 170 – 174
Zaman GJR, Flens MJ, Van Leusden MR, De Haas M, Mulder HS, Lankelma J, Scheper RJ, Baas F, Broxterman HJ, Borst P (1994) The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc Natl Acad Sci USA 91: 8822 – 8826
Zaman GJR, Versantvoort CHM, Smit JJM, Eijndens EWHM, De Haas M, Smith AJ, Broxterman HJ, Mulder NH, De Vries EGE, Baas F, Borst P (1993) Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines. Cancer Res 53: 1747 – 1750